Current disease status-Recurrent cancer-Metastatic recurrence Posts on Medivizor
Navigation Menu

Current disease status-Recurrent cancer-Metastatic recurrence Posts on Medivizor

An analysis of abiraterone plus prednisone for metastatic castration-resistant prostate cancer

Posted by on Nov 8, 2017 in Prostate cancer | 0 comments

In a nutshell This study aimed to determine which patients  benefited most from abiraterone acetate (Zytiga) and prednisone (Deltasone). This study found that overall survival was increased for all patient groups that received this combination.  Some background A main treatment option for prostate cancer is androgen deprivation...

Read More

Dabrafenib combined with trametinib is associated with durable responses in metastatic melanoma

Posted by on Jun 28, 2017 in Melanoma | 0 comments

In a nutshell This study investigated the effectiveness and safety of combined treatment with dabrafenib (Tafinlar) and trametinib (Mekinist) in patients with BRAF mutated stage 3 or 4 melanoma. Researchers suggested that the combination treatment has durable (3 years or more) results.   Some background Patients with metastatic (spread to...

Read More

The effectiveness and cardiac safety of CMF plus trastuzumab in HER2-positive metastatic breast cancer

Posted by on Apr 13, 2017 in Breast cancer | 0 comments

In a nutshell This study investigated the safety and effectiveness of treatment with combination cyclophosphamide (Cytoxan), methotrexate (Otrexup) and 5-fluoruoracil (Efudex) (CMF) plus trastuzumab (Herceptin) in HER2-positive metastatic breast cancer (MBC, cancer that has spread beyond the breast) patients. CMF plus trastuzumab (CMF+T) was found to...

Read More

Radium 223-dichloride as a treatment for castration resistant prostate cancer

Posted by on Apr 3, 2017 in Prostate cancer | 0 comments

In a nutshell This study investigated how effective and safe radium 223 dichloride treatment was in patients with castration resistant prostate cancer (CRPC). It was concluded that radium 223 dichloride increased overall survival, reduced symptomatic skeletal events risk and was safe.  Some background Treatment to decrease the male hormones,...

Read More

Comparing the safety of surgery options for patients with peritoneal metastasis

Posted by on Jan 11, 2017 in Colorectal cancer | 0 comments

In a nutshell This study investigated the safety of hyperthermic intraperitoneal chemotherapy (HIPEC) and surgery in colon cancer patients with peritoneal metastasis (PM). Researchers reported that HIPEC and surgery was associated with an increased risk of complications. Some background When colon cancer spreads to the abdominal lining (known as...

Read More

Panitumumab is associated with improved survival in metastatic colorectal cancer without KRAS or RAS mutations

Posted by on Dec 19, 2016 in Colorectal cancer | 0 comments

In a nutshell This study investigated the effect of panitumumab (Vectibix) in overall survival of patients with metastatic colorectal cancer without a KRAS or RAS mutation. Researchers suggested that panitumumab significantly improved survival in these patients.  Some background Panitumumab is a therapy that targets a...

Read More

Secondary hormone therapies: Should abiraterone or enzalutamide be administered first?

Posted by on Dec 19, 2016 in Prostate cancer | 0 comments

In a nutshell This study examined whether abiraterone (Zytiga) or enzalutamide (Xtandi) should be administered first in the treatment of metastatic castration-resistant prostate cancer. Authors report preliminary evidence for reduced disease progression when administering abiraterone before enzalutamide compared to the reverse sequence. A significant...

Read More